PATENT CLAIM ANALYSIS

Application Number: 15893261
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-11
Patent Classification: ["424", "186100"]

Abstract:
Novel nanoparticle fusion proteins comprising proteins or peptides fused to Dps (DNA binding protein from starved cells) proteins are provided which bring forth distinct advantages for development of new and improved vaccines, diagnostic tests, and other biomedical products.

Claim (Index 14):
A method of eliciting an immune response in an animal or human comprising administering to said animal or human an effective amount of Dps fusion protein of  claim 1 , wherein said Dps fusion protein is formulated in a pharmaceutically acceptable vehicle, carrier, excipient, adjuvant, or controlled release formulation.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 88.0
- Lexical Diversity: 1.10256
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14967729', '13520253', '11410572', '15289106', '12717804']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7580938002435635
- 35 USC 102 Novelty (BERT): 0.5896954109815806
- Combined Prediction Score: 0.7412539613173653
- Mean Citation Score: 404.35247
- Max Citation Score: 592.2097
- Similarity Product: 404.2124560848296

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test